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Abstract
Background: Perinatal depression among HIV-positive women has negative implications for HIV-related and
other maternal and infant outcomes. The aim of this study was to investigate the burden and correlates of
perinatal depression among HIV-positive women in Ukraine, a lower middle income country with one of the
largest HIV-positive populations in Europe.
Methods: Cross-sectional surveys nested within the Ukraine European Collaborative Study were conducted
of HIV-positive women at delivery and between 1 and 12 months postpartum. Depressive symptoms in the
previous month were assessed using a self-report screening tool. Other data collected included demographics,
antiretroviral therapy (ART)-related self-efficacy, and perceptions of risks/benefits of interventions to prevent
mother-to-child transmission (PMTCT). Characteristics of women with and without a positive depression screening test
result were compared using Fisher’s exact test and χ2 test for categorical variables.
Results: A quarter (27 % (49/180) antenatally and 25 % (57/228) postnatally) of participants screened positive
for depressive symptoms. Antenatal risk factors were living alone (58 % (7/12) vs 25 % (42/167) p = 0.02),
being somewhat/terribly bothered by ART side effects (40 % (17/43) vs 23 % (30/129) not /only slightly
bothered, p = 0.05) and having lower ART-related self-efficacy (43 % (12/28) vs 23 % (25/110) with higher
self-efficacy, p = 0.05). Postnatally, single mothers were more likely to screen positive (44 % (20/45) vs 21 % (18/84) of
cohabiting and 19 % (19/99) of married women, p < 0.01) as were those unsure of the effectiveness of neonatal
prophylaxis (40 % (20/45) vs 18 % (28/154) sure of effectiveness, p < 0.01), those worried that neonatal prophylaxis
could harm the baby (30 % (44/146) vs 14 % (10/73) not worried p < 0.01) and those not confident to ask for help
with taking ART (48 % (11/23) vs 27 % (10/37) fairly confident and 15 % (4/26) confident that they could do this).
Of women who reported wanting help for their depressive symptoms, 82 % (37/45) postnatally but only 31 %
(12/39) antenatally were already accessing peer counselling, treatment adherence programmes, support groups
or social services.
Conclusions: A quarter of women screened positive for depression. Results highlight the need for proactive
strategies to identify depressive symptoms, and an unmet need for provision of mental health support in the
perinatal period for HIV-positive women in Ukraine.
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Background
In Ukraine, a lower middle income country with one
of the most severe HIV epidemics in Europe, an esti-
mated 95,000 women are living with HIV and around
4000 infants are born to women living with HIV each
year [1, 2]. In the general population of Ukraine, the
WHO World Mental Health Survey (2001-03) found
the 12-month prevalence of mood disorder to be 9.1 %
(the second highest of 14 countries surveyed) [3], and the
12-month prevalence of major depressive disorder among
women to be 11.3 %, with unmarried women and those
with low educational or socioeconomic status at increased
risk [4]. Little information is available on the mental
health of HIV-positive women living in Eastern Europe,
but studies from other settings (mainly North America
and Africa) have shown high prevalence of perinatal de-
pression in this patient group linked with a range of fac-
tors including socioeconomic adversity, intimate partner
violence and HIV-related stigma [5]. Pregnancy and the
postnatal period are times of heightened depression risk
regardless of HIV status [6, 7]. This risk may be further
compounded in HIV-positive women by inequalities in ac-
cess to support and services and by the HIV diagnosis it-
self [8, 9] which, for about 60 % of HIV-positive women
delivering in Ukraine each year, has occurred during that
pregnancy [10].
Adverse consequences of maternal depression for
women living with HIV and their children may include a
negative impact on uptake of and adherence to interven-
tions to prevent mother-to-child transmission (PMTCT)
[11, 12] and on maternal HIV disease outcomes beyond
pregnancy [13, 14], as well as increased risk of preterm
delivery [15] and of developmental and behavioural
problems in the child [16, 17]. Screening for depression
is not currently part of routine perinatal or HIV care in
Ukraine, and mental health services – historically deliv-
ered in secondary care – are highly stigmatised [18]. The
aim of this analysis was to investigate the burden and
correlates of perinatal depression among women living
with HIV in Ukraine.
Methods
Design, setting and participants
Two cross-sectional surveys (hereafter referred to as
the ‘antenatal survey’ and ‘postnatal survey’) were
conducted among HIV-positive women attending for
obstetric and/or HIV care in Ukraine between July to
December 2011, with extension to April 2012 for
some sites. The primary objective of the surveys was
to measure adherence to antiretroviral therapy (ART)
in pregnancy and postnatally [19]. The current study
is a secondary analysis of survey data, to investigate
prevalence of and factors associated with depressive
symptoms in this study population.
The antenatal survey was conducted among HIV-
positive women giving birth at one of three participating
maternity hospitals in Kiev, Odessa and Simferopol and
having received ART for at least the last four weeks of
their pregnancy (i.e. engaged in HIV care in pregnancy).
The survey was completed during the hospital stay fol-
lowing delivery (typically of ≥3 days), with retrospective
self-report of depressive symptoms experienced during
the last month of pregnancy. Clinicians at study sites
identified eligible women, provided them with written
and verbal information on the study, and gave them an
anonymous paper-based questionnaire (in Russian) to
complete if they consented to participate. The postnatal
survey was conducted among HIV-positive women at-
tending one of six participating regional HIV/AIDS cen-
tres (in Kiev, Odessa, Mykolaiv, Donetsk, Kriviy Rig and
Simferopol) between 1 and 12 months postpartum.
Women were eligible regardless of treatment history,
and were identified and invited to participate by their
clinician during the course of routine infant follow-up
and ongoing HIV care, with informed consent proce-
dures as for the antenatal survey.
These surveys were nested within the infrastructure of
the European Collaborative Study (ECS) in EuroCoord
(www.eurocoord.net), a multi-site observational cohort
study of HIV-infected pregnant women and their infants
enrolling women in Ukraine since 2000 [10], however
ECS enrolment was not a pre-requisite for survey par-
ticipation. The anonymous individual patient survey data
were matched to patient records in the ECS database
using four variables (maternal date of birth, date of de-
livery, infant sex and centre), to give additional informa-
tion on clinical characteristics.
Depression screening tool and other measures
In the antenatal and postnatal surveys, the Patient
Health Questionnaire (PHQ)-2 Screening Questions
from the Primary Care Evaluation of Mental Disorders
[20] were used to identify depressive symptoms (i.e. an-
hedonia and low mood) over the past month. These two
questions are as follows: ‘During the past month, have
you often been bothered by feeling down, depressed or
hopeless?’, and ‘During the past month, have you often
been bothered by little interest or pleasure in doing
things?’ Each question has a yes/no response. A partici-
pant was considered to have a positive depression
screening test result if she responded ‘yes’ to both of
these questions, or if she answered ‘yes’ to either one
and also responded positively to the follow-on question
‘Is this something you feel you need or want help with?’
(i.e. responded ‘yes’ or ‘yes but not today’, rather than
the remaining option of ‘no’) [21]. ART-related self-
efficacy was measured using five questions adapted from
the AIDS Clinical Trials Group Center for AIDS
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Prevention Studies HIV Treatment Adherence Self-
Efficacy Scale [22]. These questions asked about her
level of confidence to perform various behaviours over
the last four weeks, for example, to keep taking medica-
tion even if side effects began to interfere with her daily
activities, and to keep taking medication even if in front
of people who were not aware of her HIV status. The
questionnaire also included questions about health be-
haviours, HIV status disclosure, experience of ART side
effect and help-seeking self-efficacy [22]. Perceptions of
the risks and benefits of ART for PMTCT were assessed
using questions adapted from the NIAIDS Adult AIDS
Clinical Trials Group supplemental antepartum adher-
ence questionnaire [23]; women were asked how sure
they felt that antenatal ART (antenatal survey) or neo-
natal prophylaxis (postnatal survey) were effective for
PMTCT and how worried they were about these inter-
ventions harming their baby.
Statistical analysis
Survey data from 10 respondents (five in the antenatal
survey and five in the postnatal survey) who did not
complete the two depression screening questions on an-
hedonia and low mood were excluded from the analysis.
Seven women in the antenatal survey and ten in the
postnatal survey who self-reported anhedonia or low
mood but did not answer the follow-on question about
need for help were categorised as screen-negative in the
main results, and screen-positive in a sensitivity analysis.
The responses of 11 women who participated in the
antenatal survey and later in the postnatal survey were
included in results for both groups. Characteristics of
women screening positive and negative for depression
were compared using the Fisher’s exact test and the
χ2test for categorical variables; unless otherwise
stated, p-values were obtained using two-sided Fisher’s
exact tests. A probability of 0.05 was used to define
statistical significance. Data were managed using
REDCap electronic data capture tools hosted at Univer-
sity College London Institute of Child Health [24]. Statis-
tical analyses were performed using STATA version 12.1
(StataCorp, LP, College Station, Texas, USA).
Ethics, consent and permissions
Consent was given verbally, reflecting the anonymous
nature of the study, and return of a completed question-
naire was taken as documentation and evidence of a
woman’s consent to participate. As part of the survey
protocol, each completed questionnaire was reviewed by
the recruiting clinician in order to identify women
screening positive for depressive symptoms who re-
quired referral for support. This was explained in the pa-
tient information sheet. Ethical approval for these
surveys was obtained from the UCL Research Ethics
Committee (3061/001), in addition to institutional ap-
provals from participating sites. The ECS has approval
from the Great Ormond Street Hospital for Children
NHS Trust/Institute of Child Health Research Ethics
Committee.
Results
There were 180 antenatal survey respondents, giving
an estimated participation rate in the main six-month
survey period of 39-49 % [19]. Of the total 228 post-
natal survey respondents, 137 took part during July to
December 2011 at five HIV/AIDS centres enrolling
also into a postnatal cohort within the ECS; using de-
nominator data from these sites, the participation rate
for this period was estimated at 35 % (137/396). This
estimate considered only women attending the HIV/
AIDS centre for their first postnatal visit, and not
those returning for follow-up.
Overall, across both surveys, median age was 28.0
years (IQR 24.8-31.3), 19 % (79/408) of women were
single and 12 % (46/389) reported an illicit drug use
history (not including marijuana). Thirty percent (117/
386) reported that their pregnancy was unplanned. By
survey completion, 91 % (163/179) of antenatal and 95 %
(210/222) of postnatal participants had disclosed their
HIV status to at least one person; among the 79 %
(323/408) who were married or cohabiting, 87 %
(282/323) had disclosed to their partner. Among ante-
natal respondents and the 44 % (101/228) of postnatal
respondents currently on ART, a quarter (66/271) re-
ported being somewhat or terribly bothered by ART
side effects, while 20 % (28/138) antenatally and 17 %
(11/66) postnatally reported low ART-related self-
efficacy (i.e. unable to do one or more of five ART-
related activities). The proportion of women already
using one or more of the support services available as
part of HIV care (peer counselling, treatment adher-
ence programmes, support groups and social services)
was 78 % (78/100) in the postnatal group restricted
to women enrolled in Kiev, Odessa and Simferopol,
but only 32 % (58/180) in the antenatal group en-
rolled in the same cities (χ2 = 53.93 p < 0.01); the ma-
jority of these antenatal participants were using social
services only, while the postnatal participants were
more commonly using multiple services including
support groups and peer counselling (Table 1).
Around half in each survey group (93/180 antenatal
survey participants and 109/228 postnatal partici-
pants) had matched ECS data available; in this sub-
group, 57 % (52/92) and 60 % (65/109) respectively
were diagnosed as HIV-positive during their recent
pregnancy, and 22 % (18/83) and 16 % (17/104) had
WHO stage 3-4 disease (χ2 = 0.20 p = 0.66). However,
among women in the postnatal survey who had
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remained on ART after delivery, 39 % (16/41) had
WHO stage 3-4 disease vs. only 1/66 of those not on
ART postpartum, reflecting indications for treatment
outside pregnancy within clinical guidelines at that
time.
Overall, 27 % (95 % CI 21-34) (49/180) of antenatal
survey respondents and 25 % (95 % CI 20-31) (57/228)
of postnatal survey respondents had a positive depres-
sion screening test. Anhedonia was reported by 16 %
(28/180) antenatally and 20 % (46/228) postnatally and
low mood by 34 % (61/180) and 30 % (69/228) (Fig. 1a
and 1b). Among the 68 (37 %) antenatal survey partici-
pants who reported one or both symptoms, 61 answered
the follow-on question ‘is this something you feel you
need or want help with?’, of whom 39 % (n = 24)
responded ‘yes’ and a further 36 % (n = 15) responded
‘yes, but not today’; in the postnatal survey, these pro-
portions were 32 % (22/68) and 34 % (23/68) respect-
ively. Of the 21 women reporting both symptoms in the
antenatal survey, 52 % [11] reported wanting help while
postnatally this proportion was 68 % (25/37). If the
seven women in the antenatal survey and the 10 in the
postnatal survey who reported anhedonia and/or low
mood but omitted the ‘help’ question had all reported
needing /wanting help, the overall prevalence of screen
positive results would have increased from 27 % to 31 %
(56/180) in the antenatal survey and from 25 % to 29 %
(66/228) in the postnatal survey.
Factors associated with a positive depression screen-
ing test are shown in Table 2. Women living alone
(antenatal survey) or without a cohabiting partner
(postnatal survey) were at increased risk, as were those
with low ART-related self-efficacy (statistically signifi-
cant in the antenatal survey only). Postnatally, 45 % (5/11)
vs. 25 % (14/55) of women with low vs. high self-efficacy
screened positive for depression (p = 0.17). There was
some indication of an association between severity of ART
side effects and depressive symptoms during pregnancy
(Table 2, p = 0.05) but not postnatally among the sub-
group of 99 women on ART (26 % (7/27) of the screen
positive women reported being somewhat /terribly
bothered by side effects vs 22 % (16/72) of the screen
negative, p = 0.79). Antenatally, depression was more
common among the small group unsure of the effect-
iveness of ART for PMTCT although this did not reach
statistical significance (Table 2, p = 0.06), while postna-
tally it was more common among the 29 % (63/217)
unsure of the effectiveness of neonatal prophylaxis, and
Table 1 Characteristics of survey participants
Antenatal Survey (n=180) Postnatal Survey (n=228)
Median age at participation (IQR) 27.4 years (24.8, 30.9) 28.3 years (24.8, 31.9)
Marital status
Married 96/180 (53 %) 99/228 (43 %)
Cohabiting 50/180 (28 %) 84/228 (37 %)
Single 34/180 (19 %) 45/228 (20 %)
Living as only adult in household 12/179 (7 %) 28/225 (12 %)
Disclosure of HIV status
To husband/partner or family or friend(s) 162/178 (91 %) 210/222 (95 %)
To no one at all 16/178 (9 %) 12/222 (5 %)
Smoking, alcohol and drug usea
Current smoker 47/178 (26 %) 74/225 (33 %)
Current alcohol use 15/179 (8 %) 18/224 (8 %)
Ever used marijuana 25/178 (14 %) 27/228 (12 %)
Ever used illicit drugs other than marijuana 23/174 (13 %) 23/215 (11 %)
Use of support servicesa
Currently using support group 10/180 (5 %) 33/228 (14 %)
Currently using peer counselling 9/180 (5 %) 85/228 (37 %)
Currently using social services 39/180 (22 %) 82/228 (36 %)
Currently using adherence programme 4/180 (2 %) 43/228 (19 %)
On ART for 4 weeks preceding surveyb 180/180 (100 %) 101/228 (44 %)
aGroups not mutually exclusive
bReceipt of antenatal ART was one of the eligibility criteria for participation in the antenatal survey. Fewer women were on ART in the postnatal group because
Ukraine's national policy at the time of these surveys was based on WHO Option B, with pregnant women who did not yet have treatment indications for their
own health stopping ART at delivery
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the two-thirds (146/219) who worried that prophylaxis
might harm their baby (Table 2). In the postnatal sur-
vey, there was also a higher prevalence of screen posi-
tive results among women who felt unable to ask for
help with their medication (Table 2, p = 0.05).
Of the 228 women completing the postnatal survey,
timing of survey completion was available for 225; 53 %
(n = 120) participated at between 1 and 6 months post-
partum and 47 % (n = 105) at between 6 and 12 months.
There was no difference in timing of survey completion
by depression screening test result (those screening posi-
tive completed the survey at a median of 167 days after
delivery vs 172 days for those screening negative,
Wilcoxon rank-sum test p = 0.79). The proportion using
at least one support service was similar overall by de-
pression screening test result (antenatally, 31 % (15/49)
of screen positive women vs 33 % (43/131) of screen
negative, χ2 = 0.08, p = 0.78; postnatally, 81 % (46/57)
and 70 % (120/171) respectively, χ2 = 2.39, p = 0.12). Of
those who screened positive and reported wanting help
for their depressive symptoms, 80 % (36/45) in the postna-
tal group were already using at least one support service
vs. only 23 % (9/39) in the antenatal group (p < 0.01).
In the antenatal survey, prevalence of screen posi-
tive results for depression was 25 % (31/126) among
those who reported that their pregnancy was planned
Fig. 1 Responses to three depression screening questions among (a) 180 antenatal (b) 228 postnatal survey participants. The overlapping
segments indicate the women who screened positive (i.e. who reported anhedonia and low mood, or at least one of these symptoms in
addition to wanting help). A response to the question on wanting help was missing for †7 of 16 women who reported only low mood
in the antenatal survey, ‡1 of 12 women who reported both low mood and anhedonia in the postnatal survey and §9 of 19 women who reported
only low mood in the postnatal survey
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vs 35 % (17/49) among those with unplanned preg-
nancies (χ2 = 1.80, p = 0.18) while postnatally these
proportions were 24 % (35/143) and 26 % (18/68) re-
spectively (χ2 = 0.10, p = 0.76). Antenatal participants
diagnosed as HIV-positive during their most recent
pregnancy were no more likely to screen positive than
those diagnosed before pregnancy (31 % (16/52) and
28 % (11/40) respectively, p = 0.82), however in the
postnatal group there was some indication of an asso-
ciation (31 % (20/65) diagnosed during most recent
pregnancy screened positive vs 16 % (7/44) diagnosed
prior to pregnancy) although this did not reach statis-
tical significance (p = 0.11). Among married or cohab-
iting women with disclosure data available (145 in the
antenatal survey and 177 in the postnatal survey),
there was no association between disclosure of HIV
status to partner and positive screening test (ante-
natally, 29 % (34/119) of those who had disclosed
screened positive vs 15 % (4/26) of those who had
not disclosed (p = 0.22) while postnatally these pro-
portions were 21 % (34/162) and 20 % (3/15), p =
1.00). Prevalence of screen positive results was 34 %
(22/65) among women with WHO stage 1-2 disease vs. 11
% (2/18) among those with WHO stage 3-4 in the ante-
natal survey (p = 0.08) and 24 % (21/87) vs. 29 % (5/17) re-
spectively in the postnatal survey (p = 0.76).
Discussion
One in four women living with HIV in this study
screened positive for depression, with a similar preva-
lence in antenatal and postnatal surveys. Women who
had poor social support, doubts about the safety and
Table 2 Factors associated with a positive depression screening test
Positive depression screening test Fisher’s exact test
Antenatal survey
Living as only adult in household?
No 25 % (42/167) p=0.02
Yes 58 % (7/12)
Severity of ART side effects
Not bothered by side effects or only slightly 23 % (30/129) p=0.05
Somewhat or terribly bothered by side effects 40 % (17/43)
Level of confidence that antenatal ART is effective for PMTCT
Completely/fairly sure that it is effective 25 % (43/169) p=0.06
Not at all sure that it is effective 56 % (5/9)
Self-efficacy score for integration of ART into daily life
≥5 (higher self-efficacy) 23 % (25/110) p=0.05
<5 (lower self-efficacy) 43 % (12/28)
Postnatal survey
Marital status
Married 19 % (19/99) p<0.01
Co-habiting 21 % (18/84)
Single 44 % (20/45)
Can neonatal prophylaxis help prevent MTCT?
Yes 18 % (28/154) p<0.01
Not sure/No 40 % (25/63)
Ever worried that neonatal prophylaxis could harm baby
Yes/a little 30 % (44/146) p<0.01
No 14 % (10/73)
Self-rated ability to ask for support with taking medicationa
Confident I could do 15 % (4/26) p=0.05
Fairly confident could do 27 % (10/37)
Could not do 48 % (11/23)
ART – antiretroviral therapy; MTCT – mother-to-child transmission
aAvailable for 86 of the 101 women on ART at time of postnatal survey completion
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effectiveness of interventions for PMTCT, lower ART-
related self-efficacy and, during pregnancy, more severe
self-reported ART side effects, were more likely to
screen positive. Our results highlight a need for strat-
egies to identify and support women with depressive
symptoms among this high-risk population, and for spe-
cific counselling to address concerns and problems
around use of ART for PMTCT and treatment.
The self-report tool used in this study, although used
as part of routine perinatal care in the UK [25, 26], has
not yet been validated in Russian and assessment of its
sensitivity and specificity in this population was outside
of the scope of this study; we are therefore not able to
make conclusions about how well the screening tool dif-
ferentiated between women with and without symptoms
meeting diagnostic criteria for depression . It did how-
ever have a high level of acceptance among participants
in this study, indicated by the few women (10 in total)
who did not provide an answer to the screening ques-
tions on symptoms of anhedonia and low mood. In
addition, this study was limited by its cross-sectional na-
ture which precluded direct comparisons between ante-
natal and postnatal survey results, particularly for ART-
related factors, as the group of women on ART postna-
tally had more severe HIV disease than those on ART
during pregnancy (which included women receiving
ART for PMTCT only). Although approximately 80 % of
HIV-positive pregnant women discontinue ART at de-
livery in Ukraine [27], almost half of the postnatal sur-
vey participants were on ART, reflecting differential
follow-up and/or retention in HIV care of treated com-
pared with untreated women. Evidence from other
studies indicates that depression is associated with
poorer antenatal self-care and an increased risk of loss
to follow-up [5, 28–30]; the prevalence of depression
among our survey group (who were all in contact with
HIV services) may therefore not be generalizable to the
overall population of pregnant and postnatal HIV-
positive women in Ukraine.
The prevalence of depressive symptoms that we found
(around 25 %), while indicating a substantial burden of
poor mental health, is at the lower end of the prevalence
range reported in previous studies among women living
with HIV during pregnancy and the postnatal period [5].
Comparisons are problematic however due to hetero-
geneity of outcome measures and inclusion criteria used,
and a lack of data from similar middle-income settings
(previous studies have predominantly been from Africa
and the US). Increased risk of depression among women
with poorer social support, as indicated by our results
among women without a cohabiting partner, is a com-
mon theme across settings [5, 31]. The greater anxieties
and concerns around the use of ART among women
reporting depressive symptoms may reflect low levels of
knowledge and a more avoidant coping style in this
group in contrast with an active coping style in which
information and support is sought out, which is associ-
ated with lower depressive symptoms [32]. Depression
has been linked with intrusiveness of symptoms among
women living with HIV in a US study [33] and we
found a significant association between depressive
symptoms and self-reported severity of ART side-
effects in pregnancy, which may indicate multiple risks
for disengagement from treatment programmes postna-
tally in this group.
The World Mental Health Survey found that, in the
general population in Ukraine, only 17.4 % of women
with history of mood disorder had ever sought help
from a medical professional, and among women with
suicidal thoughts this proportion was only 28 % [4].
HIV-positive women’s unmet need for mental health
services may be even greater due to barriers such as a
lack of services integrated with HIV care, poorly devel-
oped outpatient infrastructure, out-of-pocket payments
for psychiatric medication, and the double-stigma asso-
ciated with HIV infection and mental health problems
[4, 34]. In our study, we did not have information on
participants’ history of depression, a possible risk factor
for subsequent depressive episodes [31], or their previ-
ous access to mental health services. Referrals for psy-
chological support were known to have been refused by
three screen-positive women and more may have de-
clined to attend, but the lack of functional linkages be-
tween HIV and psychological care in Ukraine and the
anonymous nature of the study precluded a more de-
tailed exploration of referral uptake.
Support services provided by non-governmental orga-
nisations (NGOs) such as support groups or peer coun-
selling may help to maintain or improve psychological
wellbeing of women living with HIV; however, these ser-
vices are provided on an ad hoc basis with regional vari-
ability, and our results show that they were accessed
predominantly after delivery. Women who have depres-
sive symptoms before or during pregnancy are at in-
creased risk of also experiencing these during the
postnatal period [35, 36], a time of competing priorities
and high risk for loss to follow-up, disengagement from
care and declining ART adherence [37–40]. Routine
screening and provision of support for depressive symp-
toms during pregnancy may provide an important op-
portunity to reduce the risk of loss to follow-up and
poor outcomes after delivery.
To date, studies on interventions for depression for
people living with HIV (which are predominantly
from North America, and among men) have shown a
range of strategies to be effective, particularly psycho-
logical interventions with a cognitive-behavioural
component [41]. Cognitive-behavioural interventions
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aimed at increasing self-efficacy have been associated
with reduced depressive symptoms and improved im-
munological and virological outcomes among women
living with HIV in the US [42, 43], and could be of
particular relevance to HIV-positive women in Ukraine
given the associations we report between depressive
symptoms and low ART-related self-efficacy. The
‘mothers2mothers’ programme in South Africa has
shown a beneficial impact of peer support for women
living with HIV on a range of psychosocial outcomes
during pregnancy and postnatally [44]. Some women in
our study were already receiving peer counselling; the
role of this in protecting against depressive symptoms
and related adverse maternal and child outcomes war-
rants further investigation. Further work is urgently
needed to validate screening tools, evaluate interven-
tions and improve access to mental health care for
women living with HIV in Ukraine.
Conclusions
Our results on the association between perinatal depres-
sive symptoms and poor social support, anxieties about
ART, low ART-self-efficacy and ART side effects high-
light the multiple issues that women with depressive
symptoms may face in optimising their own and their
child’s health, and specific needs for counselling around
the use of ART as well as for psychological support.
There is an unmet need for proactive strategies to iden-
tify depressive symptoms and provide tailored treatment
and support to this high-risk group of women living with
HIV.
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